Lixisenatide: difference between revisions
Diff·revision 4 → 5·03:32, 24 Nov 2024
Difference between revision 4 and revision 5 of Lixisenatide. 3 lines changed; the page grew by 255 bytes.
| Revision 4 — 00:06, 10 Nov 2024 DulaglutideDug (talk) add the peptide length to the infobox 2,047 bytes +276 | Revision 5 — 03:32, 24 Nov 2024 LotTraceLuka (talk) state which salt form the mass in the infobox refers to 2,302 bytes +255 | ||
|---|---|---|---|
| 18 | The short exposure profile produces a large gastric-emptying effect at each dose, and it is this rather than a large fasting-glucose effect that drives its glycaemic action. Its effect on glycated haemoglobin is modest by current standards.{{r|pfeffer2015}} | 18 | The short exposure profile produces a large gastric-emptying effect at each dose, and it is this rather than a large fasting-glucose effect that drives its glycaemic action. Its effect on glycated haemoglobin is modest by current standards.{{r|pfeffer2015}} |
| 19 | 19 | ||
| + | 20 | Non-attenuating emptying delay is a genuine pharmacological difference from the weekly agents and is the reason short-acting agents retain a niche where postprandial excursions are the problem.{{r|drucker2018}} | |
| + | 21 | ||
| 20 | == References == | 22 | == References == |
| 21 | {{reflist}} | 23 | {{reflist}} |
| ⋮ | ⋮ | ||
| 26 | [[Category:GLP-1 receptor agonists]] | 28 | [[Category:GLP-1 receptor agonists]] |
| 27 | [[Category:Peptide drugs]] | 29 | [[Category:Peptide drugs]] |
| + | 30 | [[Category:Cardiovascular outcome trials]] | |
| 28 | 31 |